CY1105631T1 - Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη - Google Patents

Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη

Info

Publication number
CY1105631T1
CY1105631T1 CY20061100884T CY061100884T CY1105631T1 CY 1105631 T1 CY1105631 T1 CY 1105631T1 CY 20061100884 T CY20061100884 T CY 20061100884T CY 061100884 T CY061100884 T CY 061100884T CY 1105631 T1 CY1105631 T1 CY 1105631T1
Authority
CY
Cyprus
Prior art keywords
receptor subtype
substituted
agents
ht1a receptor
carbostyryl derivatives
Prior art date
Application number
CY20061100884T
Other languages
Greek (el)
English (en)
Inventor
Shaun Jordan
Tetsuro Kikuchi
Katsuro TOTTORI
Tsuyoshi Hirose
Yasufumi Uwahodo
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105631(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of CY1105631T1 publication Critical patent/CY1105631T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20061100884T 2001-01-29 2006-06-28 Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη CY1105631T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29
PCT/JP2002/000626 WO2002060423A2 (en) 2001-01-29 2002-01-29 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists

Publications (1)

Publication Number Publication Date
CY1105631T1 true CY1105631T1 (el) 2010-12-22

Family

ID=25087808

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20061100884T CY1105631T1 (el) 2001-01-29 2006-06-28 Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη
CY20071101093T CY1108031T1 (el) 2001-01-29 2007-08-20 Υποκατασταθεντα παραγωγα της καρβοστυριλης ως συναγωνιστες υποδοχεων υποτυπου 5-ht 1a
CY20111100391T CY1111392T1 (el) 2001-01-29 2011-04-18 Υποκατασταθεντα παραγωγα της καρβοστυριλης ως συναγωνιστες υποδοχεων υποτυπου 5-ητ 1α

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20071101093T CY1108031T1 (el) 2001-01-29 2007-08-20 Υποκατασταθεντα παραγωγα της καρβοστυριλης ως συναγωνιστες υποδοχεων υποτυπου 5-ht 1a
CY20111100391T CY1111392T1 (el) 2001-01-29 2011-04-18 Υποκατασταθεντα παραγωγα της καρβοστυριλης ως συναγωνιστες υποδοχεων υποτυπου 5-ητ 1α

Country Status (19)

Country Link
EP (3) EP1621198B1 (https=)
JP (4) JP4178032B2 (https=)
KR (5) KR100601073B1 (https=)
CN (3) CN1239154C (https=)
AR (4) AR032641A1 (https=)
AT (3) ATE504293T1 (https=)
AU (4) AU2002226752C1 (https=)
BR (1) BR0206237A (https=)
CA (2) CA2429496C (https=)
CY (3) CY1105631T1 (https=)
DE (3) DE60239711D1 (https=)
DK (3) DK1712225T3 (https=)
ES (3) ES2363366T3 (https=)
MX (2) MX344556B (https=)
MY (1) MY129355A (https=)
PH (1) PH12014500937A1 (https=)
PT (3) PT1621198E (https=)
TW (2) TWI331919B (https=)
WO (1) WO2002060423A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
AU2003268026A1 (en) * 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CN1989968B (zh) * 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
CN102166359A (zh) * 2003-05-23 2011-08-31 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
ES2646326T3 (es) * 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
US4764416A (en) 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
WO1992020655A1 (en) * 1991-05-20 1992-11-26 The Upjohn Company Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
WO1994009765A1 (en) * 1992-10-23 1994-05-11 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
US6110918A (en) * 1996-05-07 2000-08-29 Pfizer Inc Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JP2000516936A (ja) * 1996-08-27 2000-12-19 アメリカン・ホーム・プロダクツ・コーポレイション ドパミンｄ２作動薬としておよび５―ｈｔ１ａリガンドとしての４―アミノエトキシインドール
EP1053235A1 (en) * 1998-02-03 2000-11-22 American Home Products Corporation Oxazole derivatives as serotonin-1a receptor agonists
WO1999052870A1 (en) * 1998-04-13 1999-10-21 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
EA009780B1 (ru) * 2001-06-19 2008-04-28 Норберт Мюллер Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
HK1061805A1 (en) 2004-10-08
DK1712225T3 (da) 2011-06-20
CN1484524A (zh) 2004-03-24
AU2005201772C1 (en) 2010-06-03
CA2700314C (en) 2012-04-24
TW200522960A (en) 2005-07-16
JP2007297405A (ja) 2007-11-15
ES2286755T3 (es) 2007-12-01
KR20070065425A (ko) 2007-06-22
KR100713607B1 (ko) 2007-05-02
BR0206237A (pt) 2003-12-23
CA2700314A1 (en) 2002-08-08
TWI331919B (en) 2010-10-21
ATE362763T1 (de) 2007-06-15
KR100601073B1 (ko) 2006-07-19
DE60239711D1 (de) 2011-05-19
TWI302832B (en) 2008-11-11
AU2002226752B2 (en) 2005-03-17
DE60210581D1 (en) 2006-05-24
HK1091403A1 (zh) 2007-01-19
CA2429496A1 (en) 2002-08-08
MX344556B (es) 2016-12-20
AU2007201701A1 (en) 2007-05-10
ES2261652T3 (es) 2006-11-16
AR099754A2 (es) 2016-08-17
EP1621198A3 (en) 2006-04-12
AU2002226752C1 (en) 2010-02-18
AR080849A2 (es) 2012-05-09
KR100825705B1 (ko) 2008-04-29
AU2009233591A1 (en) 2009-11-19
JP4178032B2 (ja) 2008-11-12
EP1621198B1 (en) 2007-05-23
JP2011184460A (ja) 2011-09-22
AR032641A1 (es) 2003-11-19
JP4896831B2 (ja) 2012-03-14
PH12014500937A1 (en) 2015-09-21
EP1355639A2 (en) 2003-10-29
JP5683010B2 (ja) 2015-03-11
KR20030065570A (ko) 2003-08-06
EP1712225A1 (en) 2006-10-18
KR100653591B1 (ko) 2006-12-05
DK1355639T3 (da) 2006-08-14
AU2007201701B2 (en) 2010-06-17
PT1355639E (pt) 2006-06-30
AU2005201772A1 (en) 2005-05-19
KR100763288B1 (ko) 2007-10-04
JP2004517937A (ja) 2004-06-17
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
DE60220325D1 (de) 2007-07-05
JP2011225587A (ja) 2011-11-10
DK1621198T3 (da) 2007-09-24
CN1239154C (zh) 2006-02-01
CN100450485C (zh) 2009-01-14
WO2002060423A3 (en) 2003-04-10
WO2002060423A2 (en) 2002-08-08
ATE504293T1 (de) 2011-04-15
PT1621198E (pt) 2007-06-08
MY129355A (en) 2007-03-30
DE60210581T2 (de) 2007-04-05
EP1355639B1 (en) 2006-04-12
MXPA03006603A (es) 2004-02-12
ES2363366T3 (es) 2011-08-02
CY1108031T1 (el) 2013-09-04
AU2005201772B2 (en) 2007-05-17
DE60220325T2 (de) 2008-01-17
KR20060085260A (ko) 2006-07-26
CA2429496C (en) 2010-10-19
PT1712225E (pt) 2011-04-18
KR20060028485A (ko) 2006-03-29
KR20050107822A (ko) 2005-11-15
ATE322894T1 (de) 2006-04-15
EP1712225B1 (en) 2011-04-06
CN1879624A (zh) 2006-12-20
EP1621198A2 (en) 2006-02-01
CY1111392T1 (el) 2015-08-05
CN1813745A (zh) 2006-08-09

Similar Documents

Publication Publication Date Title
CY1105631T1 (el) Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη
RU2324684C2 (ru) Пиримидиновые производные
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
ATE517882T1 (de) Chinolinderivate
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
EA200700099A1 (ru) Производные пиридина
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
EA200602260A1 (ru) Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам
CY1109490T1 (el) Τρικυκλικοι τροποποιητες πυρηνικων υποδοχεων στεροειδων ορμονων
NO20074781L (no) 4-Oksokinazolin-3-ylbenzamidderivater for behandling av cytokinsykdommer
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
EA200200952A1 (ru) Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
CY1108632T1 (el) Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
ATE295841T1 (de) Substituierte benzylthiazolidin-2,4-dion derivate
MXPA01007940A (es) Derivados de azabicicloalcano y usos terapeuticos de los mismos.
JOP20200079A1 (ar) مثبطات مستقبل عامل نمو البشرة
MX2024012967A (es) Derivados de piridina para el tratamiento de los trastornos psiquiatricos
MX384745B (es) Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.
NO20051901L (no) Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4